{"id":19529,"date":"2025-10-20T22:33:09","date_gmt":"2025-10-20T22:33:09","guid":{"rendered":"https:\/\/tezgyan.com\/index.php\/2025\/10\/20\/rubicon-research-ipo-lists-at-27-8-premium-should-you-buy-sell-or-hold-ipo-news\/"},"modified":"2025-10-20T22:33:09","modified_gmt":"2025-10-20T22:33:09","slug":"rubicon-research-ipo-lists-at-27-8-premium-should-you-buy-sell-or-hold-ipo-news","status":"publish","type":"post","link":"https:\/\/tezgyan.com\/index.php\/2025\/10\/20\/rubicon-research-ipo-lists-at-27-8-premium-should-you-buy-sell-or-hold-ipo-news\/","title":{"rendered":"Rubicon Research IPO Lists At 27.8% Premium: Should You Buy, Sell Or Hold? | Ipo News"},"content":{"rendered":"<p><br \/>\n<\/p>\n<div id=\"story-9639286\">\n<p><span class=\"jsx-395e0e0beb19cb6e jsx-4143937483\">Last Updated:<\/span><time class=\"jsx-395e0e0beb19cb6e jsx-4143937483\">October 16, 2025, 18:33 IST<\/time><\/p>\n<h2 id=\"asubttl-9639286\" class=\"jsx-c9f81425ec968c48 jsx-3686629047 asubttl-schema\">Rubicon Research IPO Listing: The stock is listed at a price of Rs 620 apiece on the NSE, compared with its IPO issue price of Rs 485.<\/h2>\n<figure class=\"jsx-c9f81425ec968c48 jsx-3686629047 amimg\"><img decoding=\"async\" alt=\"Rubicon Research's market capitalisation (mcap) stood at Rs 9,902.32 crore.\" title=\"Rubicon Research's market capitalisation (mcap) stood at Rs 9,902.32 crore.\" src=\"https:\/\/images.news18.com\/ibnlive\/uploads\/2021\/07\/1627283897_news18_logo-1200x800.jpg?impolicy=website&amp;width=400&amp;height=225\" loading=\"eager\" fetchpriority=\"high\" class=\"jsx-c9f81425ec968c48 jsx-3686629047\"\/><\/p>\n<p>Rubicon Research&#8217;s market capitalisation (mcap) stood at Rs 9,902.32 crore.<\/p>\n<\/figure>\n<p id=\"0\" class=\"story_para_0\"><strong>Rubicon Research IPO Listing:<\/strong> Pharmaceutical company Rubicon Research Ltd on Thursday made a strong stock market debut, with its shares listing at a premium of 27.8% over its issue price. The stock is listed at a price of Rs 620 apiece on the NSE, compared with its IPO issue price of Rs 485. The shares finally ended the day at Rs 628.20 apiece on the NSE, which is 29.53% higher than the issue price.<\/p>\n<p id=\"1\" class=\"story_para_1\">On the BSE, the stock was listed at Rs 620.2 apiece on the BSE.<\/p>\n<p id=\"2\" class=\"story_para_2\">The company\u2019s market capitalisation (mcap) stood at Rs 9,902.32 crore.<\/p>\n<p id=\"3\" class=\"story_para_3\"><strong>Rubicon Research IPO: What Analysts Say<\/strong><\/p>\n<p id=\"4\" class=\"story_para_4\">JM Financial in its IPO note said, \u201cThe turnaround in revenue and profitability demonstrates Rubicon\u2019s operational leverage, cost optimization, and value-driven export strategy. R&amp;D expense remains a double-digit percentage of revenue, fueling its strong pipeline.&#8221;<\/p>\n<p id=\"5\" class=\"story_para_5\"><strong>Key Strengths<\/strong><\/p>\n<ul class=\"listOncontentArticleUL\">\n<li>Leadership in high-value U.S. generic and specialty pharma markets<\/li>\n<li>Integrated R&amp;D, manufacturing, and regulatory expertise<\/li>\n<li>Improving margins, efficiency, and direct access to prescribers after U.S. Validus acquisition<\/li>\n<li>Strong product pipeline and consistent FDA approvals.<\/li>\n<\/ul>\n<p id=\"7\" class=\"story_para_7\"><strong>Risks<\/strong><\/p>\n<ul class=\"listOncontentArticleUL\">\n<li>High valuation (~60\u00d7 FY25 P\/E), reflecting strong future growth assumptions<\/li>\n<li>98%+ revenue from U.S.\u2014market concentration risk<\/li>\n<li>Pure play exporter\u2014exposed to currency, regulatory, and U.S. competition volatility<\/li>\n<li>Ongoing need for high R&amp;D investments and margin stability in generics.<\/li>\n<\/ul>\n<p id=\"9\" class=\"story_para_9\">The Rs 1,377.5-crore IPO received bids for 1,70,96,76,420 shares against 1,64,55,670 shares on offer, according to NSE data.<\/p>\n<p id=\"10\" class=\"story_para_10\">The Rubicon Research IPO had garnered 103.90 times subscription on the closing day of bidding on Monday. The Rs 1,377.5-crore IPO received bids for 1,70,96,76,420 shares against 1,64,55,670 shares on offer, according to NSE data.<\/p>\n<p id=\"11\" class=\"story_para_11\">The portion for Qualified Institutional Buyers (QIBs) attracted 130.26 times subscription. The category for non-institutional investors got subscribed 97.61 times and Retail Individual Investors (RIIs) received 35.47 times subscription.<\/p>\n<p id=\"12\" class=\"story_para_12\">Proceeds from the fresh issue to the tune of Rs 310 crore would be used for debt repayment, and a portion would be allocated for inorganic growth through acquisitions, strategic initiatives, and general corporate purposes.<\/p>\n<p id=\"13\" class=\"story_para_13\">Rubicon Research is a pharmaceutical formulation company with a strong focus on R&amp;D and innovation. Its portfolio includes an increasing number of speciality products and drug-device combination products targeting regulated markets, particularly the United States.<\/p>\n<p id=\"14\" class=\"story_para_14\">The company has also been expanding its manufacturing footprint. In June, it acquired Alkem Laboratories\u2019 formulations facility in Pithampur, Madhya Pradesh, in an all-cash deal worth Rs 149 crore.<\/p>\n<p id=\"15\" class=\"story_para_15\">It currently operates two US FDA-inspected R&amp;D facilities \u2014 one in India and another in Canada \u2014 along with two manufacturing plants in India accredited by multiple regulatory authorities, including USFDA, Maharashtra FDA (WHO-GMP), and Health Canada.<\/p>\n<div class=\"jsx-95088aad1b3c53cd atawrap\">\n<div class=\"jsx-95088aad1b3c53cd atadetailwrp\">\n<div class=\"jsx-95088aad1b3c53cd ataname\"><span class=\"jsx-95088aad1b3c53cd atthumb\"><\/p>\n<figure class=\"jsx-95088aad1b3c53cd\"><img decoding=\"async\" alt=\"Mohammad Haris\" title=\"Mohammad Haris\" src=\"https:\/\/images.news18.com\/ibnlive\/uploads\/2025\/07\/WhatsApp-Image-2025-07-08-at-16.46.30-2025-07-4288ce65f2e878c717819ce8b60fc7c8.jpeg?impolicy=website&amp;width=60&amp;height=60\" class=\"jsx-95088aad1b3c53cd\"\/><\/figure>\n<p><\/span><\/p>\n<div class=\"jsx-95088aad1b3c53cd attitle\"><a href=\"https:\/\/www.news18.com\/byline\/mohammad-haris-21410.html\" class=\"jsx-95088aad1b3c53cd atamail\">Mohammad Haris<\/a><\/p>\n<p>Haris is Deputy News Editor (Business) at news18.com. He writes on various issues related to personal finance, markets, economy and companies. Having over a decade of experience in financial journalism, Haris h&#8230;<span class=\"jsx-95088aad1b3c53cd aurpdebtn\">Read More<\/span><\/p>\n<\/div>\n<\/div>\n<p>Haris is Deputy News Editor (Business) at news18.com. He writes on various issues related to personal finance, markets, economy and companies. Having over a decade of experience in financial journalism, Haris h&#8230;<!-- --> <span class=\"jsx-95088aad1b3c53cd aurpdebtn\">Read More<\/span><\/p>\n<\/div>\n<\/div>\n<div class=\"jsx-c9f81425ec968c48 jsx-3686629047 artcta\"><a href=\"https:\/\/news18.co\/n18egpab\" target=\"_blank\" rel=\"noopener noreferrer\">Follow News18 on Google<\/a>. Join the fun, play <a href=\"https:\/\/www.news18.com\/games\/\">QIK games on News18<\/a>. Stay updated with all the latest business news, including <a href=\"https:\/\/www.news18.com\/business\/markets\/\">market trends<\/a>,\u00a0<a href=\"https:\/\/www.news18.com\/topics\/stocks-to-watch\/\">stock updates<\/a>,\u00a0<a href=\"https:\/\/www.news18.com\/business\/tax\/\">tax<\/a>, IPO,\u00a0<a href=\"https:\/\/www.news18.com\/business\/banking-finance\/\">banking finance<\/a>, real estate, savings and investments. To Get in-depth analysis, expert opinions, and real-time updates. Also <span data-olk-copy-source=\"MessageBody\">Download the\u00a0<a href=\"https:\/\/onelink.to\/eng-article-eop\">News18 App<\/a> to stay updated.<\/span><\/div>\n<div class=\"jsx-c9f81425ec968c48 jsx-3686629047 atbtlink fp\"><span>First Published:<\/span><\/p>\n<div class=\"rs\">\n<p>October 16, 2025, 10:20 IST<\/p>\n<\/div>\n<\/div>\n<div class=\"jsx-c9f81425ec968c48 jsx-3686629047 brdcrmb\"><a href=\"https:\/\/www.news18.com\/\">News<\/a>  <a href=\"https:\/\/www.news18.com\/business\/\">business<\/a>  <a href=\"https:\/\/www.news18.com\/business\/ipo\/\">ipo<\/a>  <span class=\"brdout\"> Rubicon Research IPO Lists At 27.8% Premium: Should You Buy, Sell Or Hold?<\/span><\/div>\n<div id=\"coral-wrap\" class=\"jsx-ba4d8f086a12294f \">\n<div class=\"jsx-ba4d8f086a12294f coral-cont\">\n<div class=\"jsx-ba4d8f086a12294f coltoptxt\">Disclaimer: Comments reflect users\u2019 views, not News18\u2019s. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our <a href=\"https:\/\/www.news18.com\/disclaimer\/\" class=\"jsx-ba4d8f086a12294f\">Terms of Use<\/a> and <a href=\"https:\/\/www.news18.com\/privacy_policy\/\" class=\"jsx-ba4d8f086a12294f\">Privacy Policy<\/a>.<\/div>\n<\/div>\n<\/div>\n<p><span class=\"jsx-c9f81425ec968c48 jsx-3686629047 rmbtn news18_read_more\">Read More<\/span><\/p>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.news18.com\/business\/ipo\/rubicon-research-ipo-lists-at-27-8-premium-should-you-buy-sell-or-hold-ws-l-9639286.html\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Last Updated:October 16, 2025, 18:33 IST Rubicon Research IPO Listing: The stock is listed at a price of Rs 620 apiece on the NSE, compared with its IPO issue price of Rs 485. Rubicon Research&#8217;s market capitalisation (mcap) stood at Rs 9,902.32 crore. Rubicon Research IPO Listing: Pharmaceutical company Rubicon Research Ltd on Thursday made&#8230;<\/p>\n","protected":false},"author":1,"featured_media":952,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[45],"tags":[],"class_list":["post-19529","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business"],"_links":{"self":[{"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/posts\/19529","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/comments?post=19529"}],"version-history":[{"count":0,"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/posts\/19529\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/media\/952"}],"wp:attachment":[{"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/media?parent=19529"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/categories?post=19529"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/tags?post=19529"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}